Inhibrx Biosciences (NASDAQ:INBX) reported quarterly losses of $(2.15) per share which missed the analyst consensus estimate of $(1.79) by 20.11 percent. This is a 23.21 percent increase over losses of $(2.80) per share from the same period last year.